Skip to main content

Harvard Bio Shares Slide 10.82 Percent as Revenue Inches Higher and Loss Turns to Profit

NEW YORK, May 6 (GenomeWeb News) -- Shares of Harvard Bioscience were down 10.82 percent, or $.42, at $3.46 in mid-afternoon trading after the company yesterday reported a 1-percent increase in revenues and a small net profit for the first quarter of 2005.


Revenues for the quarter were $22.4 million, up from $22.2 million during the same period last year. HBIO's Genomic Solutions subsidiary "continued to show improvement," according to the company. "As we have stated last quarter, we believe we have turned the corner at Genomic Solutions and are now focused on growing its revenues and profits," said CEO Chane Graziano in a company statement.


Research and development expenses were $1.9 million for the quarter, up from $1.7 million for the same period in 2004.


Net income was $200,000, or $.01 per share, compared to a net loss of $50,000, or $0 per share, during the first quarter of 2004.


As of March 31, HBIO had $12.4 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.